Day One Biopharmaceuticals, Inc. (DAWN)
Apr 21, 2026 - DAWN was delisted (reason: acquired by Servier)
21.53
+0.04 (0.19%)
Inactive · Last trade price
on Apr 22, 2026
DAWN Revenue
In the year 2025, Day One Biopharmaceuticals had annual revenue of $158.18M with 20.60% growth. Day One Biopharmaceuticals had revenue of $53.72M in the quarter ending December 31, 2025, with 83.92% growth.
Revenue (ttm)
$158.18M
Revenue Growth
+20.60%
P/S Ratio
14.06
Revenue / Employee
$888,663
Employees
178
Market Cap
2.22B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDAWN News
- 5 days ago - Servier completes the acquisition of Day One Biopharmaceuticals - PRNewsWire
- 7 weeks ago - Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 7 weeks ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
- 7 weeks ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
- 7 weeks ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
- 7 weeks ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
- 7 weeks ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
- 2 months ago - Day One Biopharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts